» Articles » PMID: 29997625

Immune Activation, Proinflammatory Cytokines, and Conventional Risks for Cardiovascular Disease in HIV Patients: A Case-Control Study in Bahia, Brazil

Overview
Journal Front Immunol
Date 2018 Jul 13
PMID 29997625
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cardiovascular events (CVE) are an increasing cause of morbi-mortality for HIV patients. The antiretroviral therapy (ART), persistent immune activation, and life style are factors that can increase CVE for such patients. We performed a case-control study to evaluate the role of coinfections and immune markers associated with CVE.

Methods: We included patients under ART, with undetectable plasma viral load ≥12 months. Patients presenting any condition of risk for CVE were considered cases, and those without CVE risk conditions were controls. History of viral infections (Epstein-Barr virus, hepatitis C virus, hepatitis B virus, and cytomegalovirus), exposure to antiretroviral drugs, time since HIV diagnosis/under ART, and life style (demographics, weight, smoking, alcohol, and illicit drug use) were assessed. CD4/CD8 nadir and current counts, nadir and current CD4/CD8 ratio, immune activation markers (CD4CD38HLADR, CD8CD38HLADR), and serum levels of eight cytokines [IL-2, IL-4, IL-6, IL-10, tumoral necrosis factor-alpha (TNF-α), interferon gamma, macrophage inflammatory proteins 1 alpha, and interferon-inducing protein (IP-10)] were measured.

Results: Two-thirds of patients were males. Cases ( = 106) were older (52.8 vs 49.5 years,  = 0.002), had higher levels of creatinine (0.97 vs 0.87 mg/dL,  = 0.002) and IL-6 (0.67 vs 0.52 pg/mL,  = 0.04) than controls ( = 114). There was no difference between groups regarding frequency of CD4CD39HLADR+ or CD8CD38HLADR+ cells. We found a significant correlation (all patients) between increased frequency of CD4CD38HLADR+ cells and levels of IP-10 ( = 0.171,  = 0.02) and TNF-α ( = 0.187,  = 0.01). Levels of IL-6 ( = 0.235,  = 0.02), TNF-α ( = 0.267,  = 0.01), and IP-10 ( = 0.205,  = 0.04) were correlated with CD4CD38HLADR+ cells, in controls. Higher frequency of CD4CD38HLADR+ cells was also correlated with levels of IP-10 ( = 0.271,  = 0.04) in patients presenting with arterial hypertension. Frequency of CD4CD38HLADR+ cells was negatively correlated with levels of IL-2 ( = -0.639,  = 0.01) and IL-6 ( = -0.0561,  = 0.03) in patients with hypercholesterolemia. No association was detected between viral infections or smoking/alcohol use and immune activation markers.

Conclusion: Our results indicate IL-6 levels are associated with increased CV risk. Activated CD4+ T cells were associated with increased levels of proinflammatory cytokines.

Citing Articles

Emerging role of natural killer cells in non-AIDS comorbidities during suppressive antiretroviral therapy.

Alles M, Demberg T, Liyanage N Curr Opin HIV AIDS. 2025; 20(2):145-153.

PMID: 39774039 PMC: 11802316. DOI: 10.1097/COH.0000000000000913.


Regulatory T cells modulate monocyte functions in immunocompetent antiretroviral therapy naive HIV-1 infected people.

Georgia A, Claudine N, Carole S, Loveline N, Abel L, Flaurent T BMC Immunol. 2024; 25(1):68.

PMID: 39402453 PMC: 11472541. DOI: 10.1186/s12865-024-00654-8.


Observational study of effects of HIV acquisition and antiretroviral treatment on biomarkers of systemic immune activation.

Kosmider E, Wallner J, Gervassi A, Bender Ignacio R, Pinto-Santini D, Gornalusse G PLoS One. 2024; 19(7):e0288895.

PMID: 38976697 PMC: 11230552. DOI: 10.1371/journal.pone.0288895.


Low-density granulocytes display immature cells with enhanced NET formation in people living with HIV.

Park J, Dean L, Heckl J, Gangcuangco L, Pedro T, Tallquist M Sci Rep. 2023; 13(1):13282.

PMID: 37587169 PMC: 10432506. DOI: 10.1038/s41598-023-40475-0.


[Abnormal Activation of T Cells in HIV-1 Infection After Antiretroviral Therapy].

Guo Y, Zhang Y, Zhu D, Gong F, Gao Y, Zhu K Sichuan Da Xue Xue Bao Yi Xue Ban. 2023; 54(2):415-421.

PMID: 36949708 PMC: 10409166. DOI: 10.12182/20230360208.


References
1.
Guaraldi G, Cossarizza A, Franceschi C, Roverato A, Vaccher E, Tambussi G . Life expectancy in the immune recovery era: the evolving scenario of the HIV epidemic in northern Italy. J Acquir Immune Defic Syndr. 2014; 65(2):175-81. DOI: 10.1097/QAI.0000000000000018. View

2.
Feinstein M, Bahiru E, Achenbach C, Longenecker C, Hsue P, So-Armah K . Patterns of Cardiovascular Mortality for HIV-Infected Adults in the United States: 1999 to 2013. Am J Cardiol. 2015; 117(2):214-20. PMC: 5308060. DOI: 10.1016/j.amjcard.2015.10.030. View

3.
Hasse B, Ledergerber B, Furrer H, Battegay M, Hirschel B, Cavassini M . Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis. 2011; 53(11):1130-9. DOI: 10.1093/cid/cir626. View

4.
Triant V, Regan S, Lee H, Sax P, Meigs J, Grinspoon S . Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. J Acquir Immune Defic Syndr. 2010; 55(5):615-9. PMC: 3036774. DOI: 10.1097/QAI.0b013e3181f4b752. View

5.
McLaren J, Michael D, Ashlin T, Ramji D . Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy. Prog Lipid Res. 2011; 50(4):331-47. DOI: 10.1016/j.plipres.2011.04.002. View